HC Wainwright Reiterates “Buy” Rating for Mural Oncology (NASDAQ:MURA)

Mural Oncology (NASDAQ:MURA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 373.68% from the company’s previous close.

Mural Oncology Stock Performance

MURA opened at $3.80 on Wednesday. The stock’s 50 day moving average price is $3.84 and its 200-day moving average price is $3.58. Mural Oncology has a one year low of $2.87 and a one year high of $5.38. The stock has a market cap of $64.68 million, a price-to-earnings ratio of -0.42 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the previous year, the company posted ($3.57) EPS. As a group, analysts predict that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Trading of Mural Oncology

Several institutional investors and hedge funds have recently made changes to their positions in MURA. Squarepoint Ops LLC lifted its position in shares of Mural Oncology by 1.4% in the 4th quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after purchasing an additional 2,470 shares during the period. Geode Capital Management LLC boosted its stake in Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Mural Oncology by 12.0% during the 4th quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock valued at $210,000 after purchasing an additional 6,993 shares during the last quarter. Northern Trust Corp boosted its position in shares of Mural Oncology by 22.0% in the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after purchasing an additional 7,197 shares in the last quarter. Finally, FMR LLC increased its position in Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares in the last quarter. 80.21% of the stock is currently owned by institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.